Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BR101 in advanced solid tumors
NCT06001580Phase 1Completed
- Sponsor
- BioRay Pharmaceutical
- Start
- Aug 2021
- Primary completion
- Oct 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ansipastobart in solid tumor (advanced stage), sponsored by BioRay Pharmaceutical. Primary endpoints: Maximum Tolerated Dose at 91 days, Recommended Phase 2 Dose at 91 days and 1 more. Started Aug 2021; status: completed.
02
Drugs
ansipastobart
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06001580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06001580.